Hess U, Jungi W F, Morant R, Schmid L, Senn H J, Bandhauer K
Medizinische Klinik C, Kantonsspital St. Gallen.
Schweiz Med Wochenschr. 1990 Dec 8;120(49):1883-6.
Since 1985 44 consecutive patients with testicular cancer have been treated with a modified BEP regimen. 70% had metastatic disease and 30% received adjuvant therapy. After mean follow-up of 26 (8-56) months, 91% of patients are alive and all are in remission. Chemotherapy-related side effects were alopecia (100%), myelosuppression (100%), nausea/vomiting (89%) and fever (66%). Patients reported nausea has been rare. It is concluded that BEP chemotherapy is a highly effective treatment which secures complete remission or cure even in patients with advanced metastatic disease. In retrospect the patients considered the treatment worthwhile despite the stress involved.
自1985年以来，44例连续的睾丸癌患者接受了改良的BEP方案治疗。70%的患者患有转移性疾病，30%接受了辅助治疗。平均随访26（8 - 56）个月后，91%的患者存活且均处于缓解状态。化疗相关的副作用包括脱发（100%）、骨髓抑制（100%）、恶心/呕吐（89%）和发热（66%）。报告恶心的患者很少见。结论是，BEP化疗是一种高效的治疗方法，即使对于晚期转移性疾病患者也能确保完全缓解或治愈。回顾来看，尽管治疗过程有压力，但患者认为这种治疗是值得的。
